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Background: Mucosal and systemic immune mediators have been
independently associated with HIV acquisition risk, but the relation-
ship between compartments remains unclear.
Methods: To address this, the concentrations of 12 cytokines were
compared in matched plasma and cervicovaginal lavages (CVLs)
from 57 HIV-positive women before their acquisition of HIV (cases)
and 50 women who remained uninfected (controls) during the
CAPRISA 004 trial.
Results: Although genital IP-10 concentrations were significantly
higher in cases, plasma IP-10 concentrations were inversely associated
with HIV risk. Comparing differences in mucosal and systemic cytokine
concentrations between cases and controls, mucosa-biased gradients
indicating higher cervicovaginal lavage relative to plasma concentrations
were observed for all 5 chemokines in the panel. Four were significantly
associated with HIV acquisition, including IP-10 (odds ratio [OR] 1.73,
95% confidence interval [CI]: 1.27 to 2.36), macrophage inflammatory
protein–1b (OR 1.72, 95% CI: 1.23 to 2.40), interleukin (IL)-8 (OR 1.50,
95% CI: 1.09 to 2.05), and monocyte chemotactic protein-1 (OR 1.36,
95% CI: 1.01 to 1.83). None of the other 7 cytokines tested predicted
HIV risk. Decision tree analyses confirmed this association, with
gradients of IP-10, IL-8, and granulocyte-macrophage colony-stimulating
factor concentrations correctly classifying 77% of HIV outcomes.
Conclusions: Our findings suggest that mucosa-biased gradients of
IP-10, macrophage inflammatory protein–1b, IL-8, and monocyte
chemotactic protein-1 are associated with an increased risk of
HIV infection.
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INTRODUCTION
Host immune factors that influence the probability of
male-to-female HIV transmission remain poorly characterized.
The immune barrier of the female genital tract generally
provides effective protection against HIV, as indicated by low
per-coital rates of HIV acquisition in the absence of trans-
mission cofactors.1–3 However, in young South African
women, studies have found extremely high per-partnership
transmission probabilities of 0.74–1.0.4,5 A better understand-
ing of the factors that may drive these high rates of HIV
acquisition is of vital importance to HIV prevention efforts.
Several investigators have hypothesized that availability of HIV
target cells at the site of transmission may be determinants of
HIV susceptibility.6 In the nonhuman primate model of simian
immunodeficiency virus (SIV) infection, elevated concentra-
tions of the chemokines macrophage inflammatory protein
(MIP)-1a, MIP-1b, MIP-3a, and interleukin (IL)-8 were shown
to be essential for establishment of a productive infection, and
blocking of these chemokines prevented target cell recruitment
and SIV infection.7 Although a relative paucity of HIV target
cells in the reproductive tract of healthy women has previously
been reported,8,9 various microbial and nonmicrobial cofactors
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have been shown to influence chemokine concentrations, which
in turn has been associated with target cell recruitment.10–14
We have previously shown that elevated concentrations
of genital tract chemokines, including IL-8, MIP-1a, MIP-1b,
and interferon gamma-induced protein (IP-10), were associ-
ated with increased risk of HIV acquisition in young South
African women participating in the CAPRISA 004 1%
tenofovir gel microbicide trial.15 Of these, MIP-1a and
MIP-1b specifically recruit CCR5+ target cells that are
required to establish HIV infection.16 IP-10 is the ligand
for CXCR3, which is expressed on a similar overlapping set
of T-helper type 1 cells as CCR5.17 In another cohort, we
similarly showed that increased concentrations of several
cytokines and chemokines (IL-1b, IL-6, IL-8, and sCD40L)
in cervicovaginal lavage (CVL) secretions were associated
with HIV outcome.12 These findings are supported by recent
work suggesting that elevated genital concentrations of the
CCR5-binding chemokine, RANTES, were associated with
an increased risk of HIV infection.18
Systemic immune mediators also predict risk for HIV
seroconversion, although findings in these immunological
studies have been somewhat inconsistent. Kahle et al19 showed
that increased levels of IL-10 and IP-10 in blood were associated
with HIV transmission when present in both the uninfected and
infected sexual partners with HIV. Another prospective cohort
study observed lower systemic IL-6 and IL-10 and higher IL-7
concentrations in those who eventually acquired HIV, but only
in univariate analyses.20 Previously, our group also demon-
strated that systemic tumor necrosis factor (TNF)-a, IL-2, IL-7,
and IL-12p70 concentrations were elevated in women who later
became HIV-infected compared with those who remained
uninfected in the CAPRISA 004 trial.21
Although it has been shown separately that both female
genital tract and systemic immune mediators can predict altered
rates of HIV acquisition, the relationship between compartments
remains unclear. In addition, most previous studies have focused
on cytokines individually, considering them either univariately,
or in a step-wise fashion with logistic regression. Here, we
sought to reconcile the contribution of the genital environment
and systemic compartments by directly comparing the relation-
ship between HIV outcome and cytokines within compartments,
and with genital and plasma cytokines in the same participants.
These data suggest that the systemic–mucosal chemokine gra-
dient may play a particularly important role in HIV acquisition,
and lend further support to the hypothesis that increased traf-
ficking of immune cells to the site of exposure might be a crit-
ical factor for establishment of HIV infection in humans.
METHODS
Study Participants
The CAPRISA 004 1% tenofovir gel microbicide trial
included 889 HIV-uninfected South African women from both
the rural Vulindlela and the urban eThekwini clinics.22 This
investigation of systemic and genital cytokines was conducted in
57 women who acquired HIV during the 2.8 years of follow-up
(cases), and 50 women who remained uninfected during the
study (controls), all of whom had CVL and plasma samples
collected from the same visits. Forty-nine cases and controls
were matched on the basis of study arm and time of sampling.
HIV testing was conducted monthly using 2 rapid HIV antibody
tests and confirmed with 2 independent RNA–polymerase chain
reaction assays at least 1 week apart.22 All samples from cases
were analyzed for cytokine levels before HIV infection [median
4.5 months preinfection (interquartile range 2.4–6.9 months)].
Research Ethics Committees at the Universities of KwaZulu-
Natal and Cape Town approved the study, and all participants
provided written informed consent before participation.
Sample Collection
CVL samples were collected by repeatedly bathing the
cervix with 3 mL sterile saline, with collection from the
posterior fornix followed by aspiration into a plastic bulb
pipette. Samples were centrifuged and the supernatant stored at
280°C. CVL samples were not collected from menstruating
participants, in which case sampling was postponed to the
following week. At the same visits, blood was collected by
venipuncture into acetate citrate dextran vacutainer tubes and
isolated blood plasma was stored at 280°C. The samples
included in this study had not been previously thawed. Before
cytokine measurements, samples were filtered by centrifugation
using 0.2 mm cellulose acetate filters (Sigma, St Louie, MO).
Measurement of Cytokine Concentrations
We previously assessed genital inflammation in 58
control participants who remained HIV uninfected during the
CAPRISA 004 trial, and in 58 matching cases before
infection.15 For this purpose of comparable systemic cytokine
assessment, the same panel of cytokines was extended to the
plasma of all women with matching plasma specimens available
(n = 107). In brief, the concentrations of IL-1a, IL-1b, IL-6, IL-
7, IL-8, IL-10, granulocyte-macrophage colony-stimulating
factor, IP-10, monocyte chemotactic protein-1, MIP-1a,
MIP-1b, and TNF-a were measured preinfection (median of
20 weeks preinfection, range 2–71 weeks) using Milliplex High
Sensitivity and Human Cytokine kits according to the manu-
facturer’s protocol (Millipore, Billerica, MA). Data were
collected using a Bio-Plex Suspension Array Reader (Bio-Rad
Laboratories Inc., Hercules, CA) and a 5 PL regression formula
was used to calculate sample concentrations from the standard
curves. Data were analyzed using Bio-Plex manager software
(version 4). Cytokine levels that were below the lower limit of
detection of the assay were reported as the mid-point between
zero and the lowest concentration measured for that given
cytokine. Detection limits of the cytokines measured in both
genital and blood specimens are listed in Supplemental Digital
Content 1, http://links.lww.com/QAI/A939.
Statistical Analyses
Statistical analyses were performed using GraphPad
Prism version 5 (GraphPad Software, San Diego, CA),
STATA (StataCorp, College Station, TX), SAS version 9.3
(SAS Institute Inc., Cary, NC), and Matlab (Matlab 2014a;
MathWorks, Natick, MA). Cytokine concentrations were
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log10-transformed. Conditional logistic regression was used with
matched pairs as strata to determine the association between
log10-transformed plasma cytokine concentrations and risk of
HIV infection. Cytokine gradients were calculated as the ratio of
log10-transformed, standardized genital over plasma cytokine
concentrations. McNemar test was used to compare cases and
controls in Table 1. P-values were adjusted for multiple
comparisons using a false discovery rate step-down procedure.
We used decision tree analysis (DTA) to determine the
hierarchical importance of plasma and CVL cytokine con-
centrations in classifying HIV infection outcome.23 A classi-
fication decision tree algorithm (Matlab 2014a; MathWorks)
was used to predict infection status as a function of the CVL
and systemic cytokine measurements made from each
corresponding participant. Gini Diversity Index was chosen
as the split criterion. Cross-validation was performed by
TABLE 1. Demographic and Behavioral Characteristics of Study Participants
Women With Matched
Blood and Genital






Age [median (IQR)], yrs 22 (20–25) 22 (20–24) 22 (20–26)
% Rural (n) 68.2 (73) 67.4 (33) 71.4 (35)
% Completed high school (n) 41.1 (44) 42.9 (21) 36.7 (18)
% Ever given birth (n) 76.6 (82) 75.5 (37) 77.6 (38)
% Married (n) 5.6 (6) 2.0 (1) 10.2 (5)
% Stable partner (n) 91.6 (98) 95.9 (47) 87.8 (43)
Median number of sexual partners in lifetime (IQR) 2 (1–3) 2 (1–3) 2 (1–3)
Percentage of people who always used a condom during
sex (n)
29.9 (32) 32.7 (16) 26.5 (13)
Baseline contraception, % (n)
Injectable 86.9 (93) 89.8 (44) 83.7 (41)
Oral contraceptive pill 11.2 (12) 10.2 (5) 12.2 (6)
Tubal ligation/hysterectomy 1.9 (2) 0.0 (0) 4.1 (2)
% Baseline genital discharge 26.2 (28) 32.7 (16) 18.4 (9)
Returned used applicators per month [median (IQR)] 6 (4–9) 8 (6–10) 6 (4–7)*
Reported sexual intercourse per month [median (IQR)] 5 (3–7) 5 (3–8) 4 (3–6)
% Tenofovir gel users (n) 39.3 (42) 38.8 (19) 38.8 (19)
*P , 0$05 on a Wilcoxon signed-rank test for paired data.
IQR, interquartile range.















IL-1b 49.0 (24) 67.3 (33) 1.90 (0.88 to 4.09) 0.100 6.12 (1.45 to 25.75) 0.014*
IL-1a 10.2 (5) 12.2 (6) 1.20 (0.37 to 3.93) 0.763 1.34 (0.26 to 6.96) 0.725
IL-7 26.5 (13) 36.7 (18) 1.83 (0.68 to 4.96) 0.232 3.43 (0.92 to 12.80) 0.067
IL-8 71.4 (35) 73.5 (36) 1.11 (0.45 to 2.73) 0.819 0.98 (0.30 to 3.22) 0.971
IL-10 40.8 (20) 51.0 (25) 1.56 (0.67 to 3.59) 0.301 1.39 (0.45 to 4.33) 0.565









IL-6 20.15 (20.74 to 0.09) 20.04 (20.57 to 0.35) 1.50 (0.95 to 2.35) 0.079 1.98 (0.97 to 4.05) 0.060
GM-CSF 20.11 (20.41 to 0.13) 0.09 (20.30 to 0.37) 1.40 (0.76 to 2.59) 0.280 1.65 (0.72 to 3.82) 0.238
TNF-a 0.58 (0.30 to 0.77) 0.63 (0.51 to 0.72) 3.63 (0.72 to 18.28) 0.118 8.81 (1.14 to 68.14) 0.037*
IP-10 2.31 (2.16 to 2.51) 2.10 (1.98 to 2.35) 0.04 (0.01 to 0.37) 0.004 0.01 (0.00 to 0.19) 0.004*
MCP-1 2.14 (1.95 to 2.34) 2.17 (1.99 to 2.24) 0.43 (0.12 to 1.50) 0.186 0.31 (0.05 to 2.07) 0.227
MIP-1b 1.42 (1.25 to 1.47) 1.34 (1.10 to 1.49) 0.81 (0.26 to 2.55) 0.724 0.44 (0.08 to 2.35) 0.335
*Statistically significant after adjusting for hormone contraception use, HSV-2 status, study site, age, the number of reported sex acts during the trial, condom use during the trial,
and the number of returned used applicators.
CI, confidence interval; GM-CSF, granulocyte-macrophage colony-stimulating factor; IQR, interquartile range; MCP-1, monocyte chemotactic protein-1.
Liebenberg et al J Acquir Immune Defic Syndr  Volume 74, Number 3, March 1, 2017
320 | www.jaids.com Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc.
generating decision trees after iteratively excluding samples in
groups of ;10, then testing excluded data using the generated
model. Decision tree calibration and cross-validation error
were determined by comparing the predicted and actual class
for each individual. Reported cross-validation error for each
model reflects the average of 10 simulations performed during
the cross-validation. To prevent over-fitting, all trees were
pruned to levels with lowest cross-validation and calibration
error. For each model, the number of terminal nodes for the
optimal pruned tree was selected by minimizing both calibra-
tion and cross-validation error (See Supplemental Digital
Content 2, http://links.lww.com/QAI/A939, which illustrates
the pruning of decision trees).
RESULTS
Plasma Cytokines and the Risk of
HIV Acquisition
The concentrations of 12 cytokines were measured in
plasma samples from 57 cases and 50 controls. Of the several
demographic and behavioral characteristics assessed, only the
number of returned used applicators per month differed
significantly between cases and controls (Table 1). After
adjusting for relevant confounders hormone contraception
use, herpes simplex virus-2 status, study site (urban versus
rural), age, the number of reported sex acts during the trial,
condom use during the trial, and the number of returned used
applicators in the multivariate analyses,15,22 3 cytokines (IP-10,
TNF-a, and IL-1b) were associated with HIV as an outcome
(Table 2). These data suggest that plasma cytokines are useful
immunological measures for predicting differences in HIV risk.
Mucosa-Biased Chemokine Gradients Are
Independent Predictors of HIV Acquisition
Based on our previous finding that genital tract IP-10
concentrations were significantly higher in women who sub-
sequently seroconverted compared with those who remained
uninfected,15 and the current observation of lower plasma
IP-10 concentrations associated with HIV risk in matched
participants, we investigated the impact of mucosal–systemic
FIGURE 1. Mucosal–plasma chemokine gradients in women who remained uninfected (controls; n = 50) and in HIV- women who
subsequently acquired HIV (cases; n = 57) during the CAPRISA 004 trial. Intercompartmental cytokine gradients were determined
by quantifying the difference between standardized cytokine concentrations of the female genital tract and blood plasma for each
participant. Four of the 5 gradients associated with HIV outcome in multivariate analysis are depicted here: (A) IP-10, (B) MIP-1b,
(C) IL-8, and (D) monocyte chemotactic protein-1 (MCP-1). “Positive” gradients are indicative of higher relative levels in the
genital tract compared with the blood.
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chemokine gradients on HIV acquisition risk. Cytokine gra-
dients were determined by quantifying the difference between
standardized cytokine concentrations of the genital mucosa and
plasma on a per-individual basis. In this analysis a “positive
gradient” was indicative of higher relative levels in the
genital tract compared with the plasma. Logistic regression
analyses demonstrated that a positive gradient was associ-
ated with HIV outcome for 4 of the 5 chemokines
represented in the panel (IP-10, MIP-1b, IL-8, and mono-
cyte chemotactic protein-1), and no other cytokine (Fig. 1;
Table 3). The MIP-1a gradient trended toward a significant
association with increased HIV acquisition risk. The data
suggest that increased chemotaxis of immune cells to the
mucosal tissue is an important factor determining risk, rather
than a generalized inflammatory effect.
Hierarchical Relationships Between Systemic
and Mucosal Cytokines and HIV Outcome
Colinearity is a common drawback of using logistic
regression for multiplex cytokine analyses, because cytokines
are often highly correlated within the same sample,
precluding their entry in multivariate step-wise analyses
because of violations of key assumptions of these models.
To overcome this, we used DTA, a multivariate compu-
tational technique that emphasizes contingent rather than
independent contributions of cytokines and chemokines to
classifying women based on HIV outcome.23,24 DTA was
applied to (1) the complete data set of plasma and CVL
cytokine measurements (Fig. 2A) and (2) the complete set
of gradient measurements (Fig. 2B), and used to identify
the most influential combination of cytokine measure-
ments associated with HIV outcome (Fig. 2). In the tree
generated from combined CVL and plasma data, genital
tract MIP-1b was identified as the most influential
cytokine node, with 41/57 (71.9%) cases having genital
MIP-1b concentrations greater than 1.8 pg/mL (Fig. 2A).
Other key nodes selected by the decision tree algorithm
were plasma IL-1b and plasma IP-10, both of which were
higher in women who became infected. Overall, the
optimally pruned tree was able to differentiate women
based on infection status with 80% calibration accuracy
(Fig. 2E) and 67% cross-validation accuracy (Fig. 2F).
To identify the hierarchical importance of cytokine
gradients associated with HIV risk, a second decision tree
was modeled to include the 12 cytokine gradients
described. Interestingly, in this analysis the decision tree
algorithm identified IP-10, IL-8, and granulocyte-
macrophage colony-stimulating factor as key cytokine
gradients and a pruned tree using these nodes was able
to classify individuals with 82% calibration accuracy and
68% cross-validation accuracy (Fig. 2B). Separate CVL
(Fig. 2C) and plasma (Fig. 2D) cytokine decision trees
demonstrated that, of the cytokines measured, genital
cytokine concentrations predicted HIV infection outcome
more accurately than plasma cytokine concentrations.
However, of all the means of investigating immune
mediators of HIV risk assessed here, the models of
gradient contributions and combined CVL and plasma
cytokine contributions were most accurate by virtue of
their reduced calibration (Fig. 2E) and cross-validation
errors (Fig. 2F).
DISCUSSION
Understanding host predictors of HIV risk has
important implications for risk profiling and design of
better HIV prevention methods. Immune associations of
HIV transmission have been proposed at both mucosal and
systemic levels; however, findings from systemic samples
in particular have not been consistent across studies.19–21
In light of these differences, the primary goal of this
investigation was to understand how relative cytokine
levels in systemic and mucosal compartments at the same
preinfection time point impact the risk of HIV serocon-
version. We previously described separately the genital15
and systemic21 cytokine associations with HIV risk in 2
different subsets of women within the same trial. A major
strength of this study was the ability to evaluate paired
mucosal and systemic specimens from the same cases and
controls at the same visits using a single cytokine panel.
The term gradient refers here not to the classical indication
of a standard change in magnitude for example, of
cytokines in one compartment relative to the other, but
rather to the difference in standardized concentrations of
cytokines between compartments, where positive differ-
ences or slopes were indicative of mucosa-biased or
elevated genital concentrations relative to blood. Our data
demonstrate that the relative intercompartmental differ-
ences in concentrations of all of the chemokines assessed,
in particular, were independent predictors of HIV acqui-
sition. The definitive association with chemokines sug-
gests a mechanism focused on immune cell recruitment,
TABLE 3. Relationship Between Mucosa–Plasma Cytokine
Gradients and Risk of HIV Infection in Women From the
CAPRISA 004 Trial
Function Cytokine OR 95% CI P Adjusted,* P
Chemokine IP-10 1.73 1.27–2.36 0.001 0.002†
MIP-1b 1.72 1.23–2.40 0.001 ,0.001†
IL-8 1.50 1.09–2.05 0.012 0.003†
MCP-1 1.36 1.01–1.83 0.042 0.007†
MIP-1a 1.28 0.96–1.71 0.095 0.057
Proinflammatory IL-1a 1.18 0.87–1.60 0.294 0.274
IL-1b 0.90 0.68–1.19 0.450 0.614
IL-6 0.87 0.66–1.14 0.304 0.729
TNF-a 0.99 0.75–1.31 0.943 0.682
Hematopoeitic GM-CSF 1.09 0.82–1.46 0.555 0.316
IL-7 0.95 0.73–1.23 0.683 0.966
Anti-inflammatory IL-10 1.06 0.79–1.42 0.707 0.267
*Adjusted for treatment arm, age, urban/rural site, baseline hormonal contraception,
baseline HSV-2 status, mean number of sex acts reported during trial, median number of
returned used applicators, proportion of last sex acts covered by condom use.
†Statistically significant after adjusting for multiple comparisons using a false
discovery rate step-down procedure.
CI, confidence interval; GM-CSF, granulocyte-macrophage colony-stimulating
factor; MCP-1, monocyte chemotactic protein-1.
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because this is the primary physiological function of
chemokines. Indeed, we have recently demonstrated that
increased concentrations of several chemokines in the
female genital tract correlate with increased frequencies of
endocervical CD4+ T cells.25 A study of highly exposed
but seronegative (HESN) sex workers reported similar
FIGURE 2. Decision tree analyses to iden-
tify the most influential combinations of
genital and plasma, cytokine measurements
associated with HIV outcome. Cytokine
concentrations determined in cases (n = 57)
and controls (n = 50) were modeled to
include (A) the concentrations of all 12
cytokines in genital and plasma specimens,
(B) mucosal-Plasma gradients, (C) all 12
genital cytokines alone, or (D) all 12 plasma
cytokines. Comparison of the (E) calibration
and (F) cross-Validation errors for decision
trees generated using either plasma, CVL,
combined CVL and plasma, or cytokine
gradients, respectively.
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results with respect to reduced levels of IP-10, MIP-1a,
and MIP-1b in the genital tract relative to plasma.26,27
These data are also in line with data from the nonhuman
primate model of SIV transmission,7 where chemokine
production preceded the recruitment of essential CD4+
T-cell target cells to the female genital tract, and high-
lighted the potential role of local MIP-1a and MIP-1b
concentrations in the establishment of productive SIV
infection. Further studies to link this hypothesis empiri-
cally to HIV acquisition in human cohorts will be
important to validate these findings.
Despite the differences between compartments,
several systemic cytokines were associated with HIV
acquisition, including those that support and extend a pre-
vious study of plasma cytokines in the same cohort.21 Our
study corroborates a trend of increased IL-7 in cases
compared with controls as previously reported.21 How-
ever, the association between lower IP-10 in blood and
increased HIV acquisition risk is contrary to the findings
of Kahle et al, who found increased IP-10 in plasma
associated with increased HIV risk in discordant cou-
ples.19 Lehman et al20 did not report any significant
differences between cases and controls with respect to
systemic cytokines, but their panel did not include chemo-
kines other than IL-8.
That several genital tract chemokines were positively
associated with HIV outcome while plasma IP-10 was
inversely associated suggests that mucosal stimuli might
drive the chemokine gradient by interacting with epithelial
cells or resident immune cells (CD8 T cells, dendritic cells,
macrophages, and natural killer cells) via pattern recognition
or other innate immune receptors.28,29 This hypothesis is
supported by the finding that most plasma chemokines did
not correlate between cases and controls,15 indicating that
cytokines are likely produced in the female genital tract in
response to localized stimuli, and reinforces the importance
of assessing mucosal specimens. Indeed, of the decision tree
models, the mucosa-only analysis was superior to the
plasma-only tree in terms of classifying cases and controls.
However, the combined or gradient decision tree algorithms
were the most consistent and were the preferred models for
classifying the cases and controls in comparison. These data
support a model whereby the plasma analysis might detect
more “global” immunological differences between cases and
controls, whereas mucosal chemokine concentrations reflect
processes and/or cofactors that operate locally as mediators
of HIV risk.
We acknowledge several limitations of this study.
Although every effort was made to include all relevant
specimens in this study, our sample size was limited by the
number of seroconversions in the CAPRISA 004 study, the
number of participants who consented to sample storage, and
on the sample availability pre-HIV infection. Although the
selected panel of 12 cytokines includes those known to play
important roles in inflammatory conditions,11,12,15 it is likely
that additional cytokine associations could be observed if
a larger cytokine panel was measured. However, because
multiple chemokines can bind the same receptors, the
inclusion of 5 key chemokines covers a broad range of
immunological effects. It is interesting to note that associa-
tions with HIV risk were not limited to CCR5 ligands. IP-10
is the ligand for CXCR3, a Th1 marker,30 and a role for
CXCR3 ligands has been implicated in various animal models
of mucosal viral infection.31,32 CCR5 is also highly expressed
on Th1 cells, so some overlap between these chemokines/
chemokine receptors is expected. Another limitation was that
the dilution factors of CVL specimens were not known,
whereas plasma was undiluted. We addressed the sampling
differences by first standardizing the genital and plasma
cytokine measurements to allow their equal contribution to
the scale before calculating mucosa-plasma ratios. The
differences between genital and plasma cytokine concentra-
tions observed for each woman was therefore relative to the
other study participants. Moreover, the specificity of the
association with chemokine rather than cytokine gradients is
strongly suggestive that the chemokine gradient might be
a useful measure and is linked to a biologically plausible
hypothesis around mucosal target cell recruitment and
increased HIV risk. Further studies are required to address
the contribution of sexually transmitted infection, hormonal
contraception, other proinflammatory agents to the chemo-
kine gradient direction, and HIV risk.
In summary, this study compared parallel cytokine
levels in blood and mucosa and linked these hierarchically
and prospectively to HIV as an outcome. These data further
underscore the importance of chemokines as determinants of
HIV acquisition. Further studies to validate these findings
could provide critical biomarkers for HIV risk profiling,
allowing accurate classification of risk to implement more
targeted HIV prevention strategies or conduct more rapid
efficacy assessments of HIV prevention candidates. Trans-
lation of these findings through safe and effective manipula-
tion of chemokine gradients, or by limiting their production or
effects, could represent a novel and targeted host-directed
HIV prevention modality.
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